RxSight, Inc. Announces Chief Financial Officer Transition
Rhea-AI Summary
RxSight (NASDAQ:RXST) announced that Shelley Thunen, its Chief Financial Officer, is transitioning from the CFO role and will remain with the company until the sooner of her successor's appointment or January 31, 2026. Ms. Thunen has agreed to support RxSight as a consultant after the transition.
The release highlights Ms. Thunen's nearly decade of service, her role in the company's 2021 IPO, and operational achievements under her finance leadership, including more than 1,100 light-adjustable intraocular devices (LDDs) in the field and over 250,000 procedures performed. The CEO and board expressed gratitude for her contributions.
Positive
- CFO will remain until successor or Jan 31, 2026
- CFO agreed to continue as a consultant after transition
- Nearly a decade of CFO tenure with company
- Finance leadership through 2021 IPO
- 1,100+ LDDs in field and 250,000+ procedures
Negative
- Current CFO role will be vacated by Jan 31, 2026, creating near-term leadership change
News Market Reaction – RXST
In the Dec 23 session, RXST declined 9.98%, reflecting a notable negative market reaction. Argus tracked a trough of -6.4% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 20 | Conference participation | Positive | -5.8% | Piper Sandler healthcare conference presentation and webcast details. |
| Nov 05 | Earnings results | Negative | -7.3% | Q3 2025 revenue decline, lower LDD sales, updated guidance. |
| Oct 22 | Earnings call notice | Neutral | -1.2% | Announcement of date and access details for Q3 2025 call. |
| Oct 16 | Product education | Positive | -2.8% | Live Learning Sessions on Light Adjustable Lens at AAO 2025. |
| Aug 25 | Conference participation | Positive | -1.3% | Planned presentation at Morgan Stanley Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent RXST headlines, including conferences and product visibility events, often coincided with negative price reactions, even when the news itself appeared neutral to positive. Only the Q3 2025 earnings event showed price action directionally aligned with a negative fundamental update.
Over the last six months, RxSight has focused on investor outreach and operational updates, presenting at the Morgan Stanley and Piper Sandler healthcare conferences and highlighting its Light Adjustable Lens platform at AAO 2025. Financially, Q3 2025 results on Nov 5 showed lower revenue and a wider loss, with guidance narrowed but margins improved. Notably, each of these prior announcements, including conference participation and earnings, was followed by a negative 24h price reaction, framing today’s CFO transition within a backdrop of recent share‑price weakness.
Key Terms
ophthalmic medical
cataract surgery medical
initial public offering financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that Shelley Thunen, the Company’s Chief Financial Officer, is transitioning from her role. Ms. Thunen will remain with the Company until the sooner of the appointment of her successor or January 31, 2026. Ms. Thunen has agreed to support the Company as a consultant subsequent to the transition.
“Shelley has been a key and trusted partner throughout some of the most important years in RxSight’s development,” said Ron Kurtz, Chief Executive Officer and President of RxSight. “Shelley developed and executed on our financial strategy, and over nearly a decade, her leadership and unwavering commitment helped guide RxSight from a pre-commerical company to one with more than 1,100 LDDs in the field and over a quarter million procedures performed. She has shaped the foundation we rely on today, and we are truly grateful for everything she has done for our patients, our customers, and everyone at RxSight.”
“Shelley has had a profound impact on RxSight,” said Andy Corley, Chairman of the Board. “Her judgment, integrity, and dedication helped guide the Company through pivotal events, including our initial public offering in 2021, and positioned RxSight for the opportunities ahead. The Board is sincerely appreciative of her service and the lasting mark she leaves on the organization.”
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
